抑制剂简介
抑制剂是一类能够降低或阻止生物体内的酶活性、受体的活性或是细胞内特定反应过程的小分子化合物。它们在有机化学、化学化工和生物医药领域中有着广泛的应用,尤其是在药物研发方面。
分类与作用机制
应用领域
总结
抑制剂的研究和发展对于理解生命过程至关重要,并在药物开发、基础科学研究等多个领域发挥着重要作用。随着技术的进步,新的抑制剂不断被发现和开发出来,为医学治疗提供了更多的可能性。
中文名称 | 英文名称 | CAS号 | 化学式 | 结构式图片 |
---|---|---|---|---|
1-[(2-氯苯基)二苯甲基]-1H-吡唑 | clotrimazole | 289905-88-0 | C22H17ClN2 |
|
1-(6,7-二氢-5H-苯并[6,7]环庚烷并[1,2-c]哒嗪-3-基)-N3-[(7S)-6,7,8,9-四氢-7-(1-吡咯烷基)-5H-苯并环庚烯-2-基]-1H-1,2,4-三唑-3,5-二胺 | R428 | 1037624-75-1 | C30H34N8 |
|
1-(4-溴-2-(1H-四唑-5-基)苯基)-3-(3-(三氟甲基)苯基)脲 | N-(3-trifluoromethylphenyl)-N’-[4-bromo-2-(1H-tetrazol-5-yl)phenyl]urea | 343630-41-1 | C15H10BrF3N6O |
|
1-(4-氟苯甲酰基)-3-[(6-甲氧基萘-2-基)氧甲基]氮杂环丁烷-3-羧酸 | PF-04418948 | 1078166-57-0 | C23H20FNO5 |
|
1-(4-吡啶基)-3-(2-喹啉基)-2-丙烯-1-酮 | (E)-1-(pyridin-4-yl)-3-(quinolin-2-yl)prop-2-en-1-one | 4382-63-2 | C17H12N2O |
|
1-(3-羟基苄基)-3-[4-(吡啶-4-基)噻唑-2-基]脲 | RKI-1447 | 1342278-01-6 | C16H14N4O2S |
|
1-(3-乙基-5-甲氧基-2(3H)-苯并噻唑亚基)-2-丙酮 | (1E)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one | 300801-52-9 | C13H15NO2S |
|
1-(3,4-二氯苄基)-1H-吲哚-2,3-二酮 | 1-(3,4-Dichlorobenzyl)-1H-indole-2,3-dione | 79183-19-0 | C15H9Cl2NO2 |
|
1-(2-羟基-2-甲基丙基)-N-(5-((7-甲氧基喹啉-4-基)氧基)吡啶-2-基)-5-甲基-3-氧-2-苯基-2,3-二氢-1H-吡唑-4-羧酰胺 | AMG 458 | 913376-83-7 | C30H29N5O5 |
|
1-(2-溴苯基)-3-(2-羟基-4-硝基苯基)脲 | 1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea | 182498-32-4 | C13H10BrN3O4 |
|
1-(2,4-二氯苯基)-5-(4-碘苯基)-4-甲基-N-1-哌啶基-1H-吡唑-3-羧胺 | 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide | 183232-66-8 | C22H21Cl2IN4O |
|
1,5,6,7-四氢-2-(4-吡啶基)-4H-吡咯并[3,2-C]吡啶-4-酮 | PHA-767491 | 845714-00-3 | C12H11N3O |
|
1,4,5,6,7,8-六氢-2,7,7-三甲基-4-(4-硝基苯基)-5-氧代-3-喹啉羧酸环己基酯 | FLI-06 | 313967-18-9 | C25H30N2O5 |
|
1,3-二氢-3-[(3,5-二甲基-1H-吡咯-2-基)亚甲基]-2H-吲哚-2-酮 | semaxanib | 204005-46-9 | C15H14N2O |
|
1,2-二氢-3H-萘并[2,1-b]吡喃-3-酮 | splitomicin | 5690-03-9 | C13H10O2 |
|
1,1'-[2-(苯基氨基)-1,4-亚苯基]二[1-[4-(1-吡咯烷基)-1-哌啶基]甲酮] | UNC1215 | 1415800-43-9 | C32H43N5O2 |
|
(±)-alpha-[[(叔-丁基)氨基]甲基]-7-乙基-2-苯并呋喃甲醇盐酸盐 | Bufuralol hydrochloride | 60398-91-6 | C16H23NO2*ClH |
|
(alphaR)-alpha-氨基-N-(5,6-二氢-2-(1-甲基-1H-吡唑-4-基)-6-氧代-1H-吡咯并(4,3,2-ef)(2,3)苯并二氮杂卓-8-基)环己烷乙酰胺 | PF-477736 | 952021-60-2 | C22H25N7O2 |
|
(aS)-N-[(1S)-2-[[(7S)-6,7-二氢-5-甲基-6-氧代-5H-二苯并[b,d]氮杂卓-7-基]氨基]-1-甲基-2-氧代乙基]-3,5-二氟-alpha-羟基苯乙酰胺 | LY-411575 | 209984-57-6 | C26H23F2N3O4 |
|
(S,Z)-N-(3-(4-(2-(5-甲基-2-苯基恶唑-4-基)乙氧基)苯基)-2-((4-氧代-4-(4-(三氟甲基)苯基)丁-2-烯-2-基)氨基)丙基)丙酰胺 | GW 6471 | 880635-03-0 | C35H36F3N3O4 |
|
(S)-马来酸噻吗洛尔 | timolol maleate | 60469-65-0 | C4H4O4*C13H24N4O3S |
|
(S)-4-氨基-N-(1-(4-氯苯基)-3-羟基丙基)-1-(7H-吡咯并[2,3-d]嘧啶-4-基)哌啶-4-羧酰胺 | AZD5363 | 1143532-39-1 | C21H25ClN6O2 |
|
(S)-4-(4-氯苯基)-N-(4-羟基苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-乙酰胺 | OTX-015 | 202590-98-5 | C25H22ClN5O2S |
|
(S)-4-(2-氨基-2-羧乙基)-N,N-双(2-氯乙基)环己-1,3-二苯胺氧化物二盐酸盐 | PX-478 2HCl | 685898-44-6 | C13H20Cl4N2O3 |
|
(S)-3-(1-((9H-嘌呤-6-基)氨基)乙基)-8-氯-2-苯基-1(2H)-异喹啉酮 | duvelisib | 1201438-56-3 | C22H17ClN6O |
|
(S)-3,5-二羟基苯基甘氨酸 | (S)-3,5-dihydroxyphenylglycine | 162870-29-3 | C8H9NO4 |
|
(S)-3,4-二氢-4-羟基-2-(3-甲氧丙基)-2H-噻吩并[3,2-E]-1,2-噻嗪-6-磺酰胺 1,1-二氧化物 | (S)-3,4-dihydro-4-hydroxy-2(3-methoxypropyl)-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide | 154127-42-1 | C10H16N2O6S3 |
|
(S)-1-[4-[[2-(2-氨基嘧啶-5-基)-7-甲基-4-(吗啉-4-基)噻吩并[3,2-D]嘧啶-6-基]甲基]哌嗪-1-基]-2-羟基丙-1-酮 | GDC-0980 | 1032754-93-0 | C23H30N8O3S |
|
(S)-1-((S)-2-环己基-2-((S)-2-(甲基氨基)丙酰胺基)乙酰基)-N-(4-苯基-1,2,3-噻二唑-5-基)吡咯烷-2-甲酰胺 | (S)-1-((S)-2-cyclohexyl-2-((S)-2-(methylamino)propanamido)acetyl)-N-(4-phenyl-1,2,3-thiadiazol-5-yl)pyrrolidine-2-carboxamide | 873652-48-3 | C25H34N6O3S |
|
(S)-(+)-N-羟基-4-(3-甲基-2-苯基丁酰氨基)苯甲酰胺 | AR-42 | 935881-37-1 | C18H20N2O3 |
|
(S)-(+)-2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-基)乙酸叔丁酯 | (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate | 1268524-70-4 | C23H25ClN4O2S |
|
(R,R)-瑞波西汀 | (2R,3R)-reboxetine | 71620-89-8 | C19H23NO3 |
|
(R)-草酸西酞普兰 | (-)-Citalopram oxalate | 219861-53-7 | C2H2O4*C20H21FN2O |
|
(R)-托特罗定L-酒石酸盐 | tolterodine tartrate | 209747-05-7 | C4H6O6*C22H31NO |
|
(R)-巴氯芬 | (R)-baclofen | 69308-37-8 | C10H12ClNO2 |
|
(R)-5-羟甲基托特罗定 | (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol | 207679-81-0 | C22H31NO2 |
|
(R)-4-(4-((4'-氯-4,4-二甲基-3,4,5,6-四氢-[1,1'-联苯]-2-基)甲基)哌嗪-1-基)-N-((4-((4-吗啉-1-(苯硫基)-2-丁基)氨基)-3-((三氟甲基)磺酰基)苯基)磺酰基)苯甲酰胺 | navitoclax | 923564-51-6 | C47H55ClF3N5O6S3 |
|
(R)-3-(2-(羟甲基)-2,3-二氢-1H-茚-4-氧基)苯基4,4,4-三氟丁烷-1-磺酸盐 | 1-Butanesulfonic acid, 4,4,4-trifluoro-, 3-(((2R)-2,3-dihydro-2-(hydroxymethyl)-1H-inden-4-yl)oxy)phenyl ester | 212188-60-8 | C20H21F3O5S |
|
(R)-3-((2-(2-(4-甲基哌啶-1-基)乙基)吡咯烷-1-基)磺酰基)苯酚盐酸盐 | SB 269970 A | 261901-57-9 | C18H28N2O3S*ClH |
|
(R)-2-氨基-7-[4-氟-2-(6-甲氧基吡啶-2-基)苯基]-4-甲基-7,8-二氢-6H-吡啶并[4,3-d]嘧啶-5-酮 | (R)-2-amino-7-[4-fluoro-2-(6-methyloxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one | 934343-74-5 | C20H18FN5O2 |
|
(R)-2-((6-((3-氯苯基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)-3-甲基丁-1-醇 | purvalanol A | 212844-53-6 | C19H25ClN6O |
|
(R)-(+)-反式-4-(1-氨基乙基)-N-(4-吡啶基)环己烷甲酰胺二盐酸盐 | (1R,4r)-4-((R)-1-aminoethyl)-N-(pyridin-4-yl)cyclohexanecarboxamide dihydrochloride | 129830-38-2 | C14H23Cl2N3O |
|
(E)-4-[2-[2-[N-乙酰基-N-[(4-甲氧基苯基)磺酰]氨基]苯基]乙烯基]吡啶1-氧化物 | HMN-214 | 173529-46-9 | C22H20N2O5S |
|
(E)-3-(对甲苯磺酰基)丙烯腈 | (E)-3-(p-tolylsulfonyl)propenenitrile | 19542-67-7 | C10H9NO2S |
|
(E)-2-氰基-3-(3,5-二叔丁基-4-羟基苯基)丙-2-烯硫代酰胺 | Tyrphostin AG 879 | 148741-30-4 | C18H24N2OS |
|
(E)-1-[2-羟基-4-甲氧基-3-(3-甲基丁-2-烯基)苯基]-3-(4-羟基苯基)丙-2-烯-1-酮 | 4-hydroxyderricin | 55912-03-3 | C21H22O4 |
|
(8S,9R)-5-氟-8-(4-氟苯基)-2,7,8,9-四氢-9-(1-甲基-1H-1,2,4-三唑-5-基)-3H-吡啶并[4,3,2-DE]酞嗪-3-酮 | talazoparib | 1207456-01-6 | C19H14F2N6O |
|
(8R)-8-(3,5-二氟苯基)-10-氧代-N-[(2R)-1,1',2',3-四氢-2'-氧代螺[2H-茚-2,3'-[3H]吡咯并[2,3-B]吡啶]-5-基]-6,9-二氮杂螺[4.5]癸烷-9-乙酰胺盐酸盐 | MK 3207 hydrochloride | 957116-20-0 | C31H29F2N5O3*ClH |
|
(6S)-2-[(3-氯-4-氟苯基)甲基]-8-乙基-1,2,6,7,8,9-六氢-10-羟基-N,6-二甲基-1,9-二氧代吡嗪并[1',2':1,5]吡咯并[2,3-D]哒嗪-4-甲酰胺 | MK-2048 | 869901-69-9 | C21H21ClFN5O4 |
|
(6R,9AR)-REL-六氢-6-[(4-羟基苯基)甲基]-8-(1-萘基甲基)-4,7-二氧代-N-(苯基甲基)-2H-吡嗪并[1,2-A]嘧啶-1(6H)-甲酰胺 | ICG 001 | 780757-88-2 | C33H32N4O4 |
|